LABP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LABP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Landos Biopharma's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Landos Biopharma's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .
Landos Biopharma's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Landos Biopharma's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .
Landos Biopharma's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Landos Biopharma's liquidation value for the three months ended in Mar. 2024 was $22.26 Mil.
The historical data trend for Landos Biopharma's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Landos Biopharma Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Change In Receivables | Get a 7-Day Free Trial | 2.09 | -0.15 | - | - | - |
Landos Biopharma Quarterly Data | ||||||||||||||||||||
Dec18 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Landos Biopharma (NAS:LABP) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Landos Biopharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Landos Biopharma's accounts receivable are only considered to be worth 75% of book value:
Landos Biopharma's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 29.004 | - | 6.742 | + | 0.75 * 0 | + | 0.5 * 0 |
= | 22.26 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Landos Biopharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Alka Batycky | director | C/O LANDOS BIOPHARMA, INC., P.O. BOX 11239, BLACKSBURG VA 24062 |
Perceptive Xontogeny Venture Fund Ii, Lp | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Roderick Wong | 10 percent owner | C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Fabio Cataldi | officer: Chief Medical Officer | C/O LANDOS BIOPHARMA, INC., PO BOX 11239, BLACKSBURG VA 24062 |
Gregory Oakes | director, officer: Chief Executive Officer | 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226 |
Patrick Truesdell | officer: Vice President and Controller | C/O LANDOS BIOPHARMA, INC., 1800 KRAFT DRIVE, SUITE 216, BLACKBURG VA 24060 |
Roger Adsett | director | 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
Josep Bassaganya-riera | director, 10 percent owner, officer: Chairman, President and CEO | 1800 KRAFT DRIVE, SUITE 100, BLACKSBURG VA 24060 |
Patricia L Bitar | officer: Interim CFO | C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122 |
Perceptive Xontogeny Venture Fund, Lp | director | C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Xontogeny, Llc | director | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Fred Callori | director | 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110 |
Joseph Edelman | director | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Life Sciences Master Fund Ltd | director | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By sperokesalga sperokesalga • 05-30-2023
By PurpleRose PurpleRose • 07-11-2022
By GuruFocusNews GuruFocusNews • 06-11-2022
By sperokesalga sperokesalga • 05-25-2023
By sperokesalga sperokesalga • 05-12-2023
By Marketwired • 09-19-2023
By sperokesalga sperokesalga • 02-28-2023
By Marketwired • 09-14-2023
By Value_Insider Value_Insider • 11-10-2022
By sperokesalga sperokesalga • 03-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.